JP Morgan Chase
JAZZ icon

JP Morgan Chase’s Jazz Pharmaceuticals JAZZ Stock Holding History

JP Morgan Chase’s Portfolio JAZZ Stock Details JAZZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-68,700
Closed -$8.45M – 7641
2023
Q4 		$8.45M Buy
+68,700
New +$8.57M ﹤0.01% 2633
2021
Q2 		– Sell
-44,800
Closed -$7.36M – 6463
2021
Q1 		$7.36M Sell
44,800
-50,000
-53% -$8.23M ﹤0.01% 2633
2020
Q4 		$15.6M Buy
94,800
+21,700
+30% +$3.23M ﹤0.01% 1825
2020
Q3 		$10.2M Buy
+73,100
New +$9.06M ﹤0.01% 2024
2018
Q3 		– Sell
-120,000
Closed -$20.7M – 5735
2018
Q2 		$20.7M Buy
120,000
+80,000
+200% +$13.1M ﹤0.01% 1551
2018
Q1 		$6.04M Buy
+40,000
New +$5.87M ﹤0.01% 2412
2017
Q4 		– Sell
-30,000
Closed -$4.44M – 5504
2017
Q3 		$4.44M Buy
+30,000
New +$4.54M ﹤0.01% 2645
2017
Q2 		– Sell
-27,000
Closed -$3.92M – 5082
2017
Q1 		$3.92M Buy
+27,000
New +$3.52M ﹤0.01% 2607
2016
Q3 		– Sell
-226,300
Closed -$32M – 4671
2016
Q2 		$32M Buy
+226,300
New +$33.4M 0.01% 1071

Other funds holding JAZZ

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
LSV Asset Management
LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

JP Morgan Chase's JAZZ Position: Q1 2026 in Review

JP Morgan Chase increased its Jazz Pharmaceuticals (JAZZ) stake by 15% in Q1 2026, buying an estimated $27.9M and bringing the position to 1,204,353 shares worth $221M. The position accounts for 0.01% of the portfolio, ranked #658.

JP Morgan Chase first reported a position in JAZZ in Q2 2013 and has held it in 52 quarters since. The position peaked at $527M in Q2 2022. 571 funds tracked by Wall St. Rank hold JAZZ as of Q1 2026.

  • JP Morgan Chase held 1,204,353 shares of Jazz Pharmaceuticals worth $221M as of Q1 2026.
  • JP Morgan Chase bought 159,711 Jazz Pharmaceuticals shares in Q1 2026, an estimated $27.9M.
  • Jazz Pharmaceuticals made up 0.01% of JP Morgan Chase's portfolio in Q1 2026, its #658 holding.
  • JP Morgan Chase first reported a position in Jazz Pharmaceuticals in Q2 2013 and has held it in 52 quarters since.
  • JP Morgan Chase's Jazz Pharmaceuticals position peaked at $527M in Q2 2022.
  • 571 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q1 2026.

Based on JP Morgan Chase's 13F filing for Q1 2026, filed 13 May 2026.